N-acetylated alpha-linked acidic dipeptidase like 2Genealiases: []
Q-omics provides the consensus-scored NAALADL2 profile across patient tissues and cancer cell-line models. NAALADL2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NAALADL2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NAALADL2 RNA expression shows 18,981 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where NAALADL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAALADL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAALADL2 survival associations across molecular data types. NAALADL2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAALADL2 RNA expression–survival associations across cancer types. High NAALADL2 expression shows unfavorable associations in LGG, but favorable associations in KIRC, LIHC, ACC, LAML and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NAALADL2 RNA expression.
This table summarizes NAALADL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAALADL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAALADL2 shows lower tumor expression in KIRC, KICH, KIRP and UCEC and higher tumor expression in LUAD and CHOL. The KIRC box plot shows higher NAALADL2 RNA expression in normal versus tumor tissue (log2 FC = −1.371, t-test p < 0.001).
This table shows molecular features associated with NAALADL2 in patient tissues and cancer cell lines. In patient samples, NAALADL2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NAALADL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
